Share This Page:   

 

Browse by Clinical Topic:
Select a Topic to Learn More

Featured CME/CE Content:

 

neuroscienceCME Editors' Picks:

Cardiovascular Comorbidities in Narcolepsy: The Latest Insights on Treatment Options to Mitigate Risks

Premiere Date: Monday, August 30, 2021

This activity offers CE credit for:

1. ABIM (MOC)
2. Medicine (accme)
3. Nursing (ANCC)
4. Pharmacy (acpe)
5. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Tuesday, August 30, 2022
Note: Credit Is No Longer Available

Faculty

Richard K. Bogan, MD, FCCP, FAASM  Associate Clinical Professor University of South Carolina Medical School, Columbia, SC Medical University of South Carolina, Charleston, SC Principal, Bogan Sleep Consultants, LLC Charleston, SC

Virend Somers, MD, PhD  Consultant, Division of Preventive Cardiology Department of Cardiovascular Medicine Alice Sheets Marriott Professor of Medicine Mayo Clinic College of Medicine and Science Rochester, MN

Statement of Need

Narcolepsy is a lifelong disorder of hypersomnolence that is associated with a high degree of disability and comorbidity. For example, patients with narcolepsy have a higher incidence of stroke, cardiovascular disease, atrial fibrillation, major adverse cardiac event, heart failure, and myocardial infarction, complicating treatment decisions. Several therapies for narcolepsy carry cardiovascular-related warnings, making treatment planning a challenge. To develop safe, effective treatment regimens for patients with narcolepsy, an understanding of the comorbidities and risk factors associated with narcolepsy is essential to optimize clinical outcomes.

This CME Outfitters Snack features expert faculty discussing the latest clinical evidence on the cardiovascular burden of narcolepsy and the need to consider cardiovascular comorbidities and other risk factors to inform treatment planning for patients with narcolepsy.

Learning Objectives

At the end of this CE activity, participants should be able to:

• Personalize treatment selection for patients with narcolepsy with or at-risk for cardiovascular comorbidities.

Financial Support

Supported by an educational grant from Jazz Pharmaceuticals, Inc.

Target Audience

Sleep specialists, pulmonologists, psychiatrists, neurologists, primary care physicians, PAs, nurse practitioners, and pharmacists

Credit Information

ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .25 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC:Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Bogan reports that he receives grants from Axsome Therapeutics, Inc.; Eisai Inc.; Flamel Technologies; Fresca Medical, Inc.; Harmony Biosciences, LLC; Idorsia Pharmaceuticals; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; Philips; Suven Life Sciences; and Takeda Pharmaceuticals U.S.A., Inc. He is a consultant for Harmony Biosciences, LLC; Jazz Pharmaceuticals, Inc.; and Takeda Pharmaceuticals, U.S.A., Inc. He is on the speakers bureau for Eisai Inc.; Harmony Biosciences, LLC; and Jazz Pharmaceuticals, Inc.

Dr. Somers reports that he receives grants from the National Institutes of Health (NIH) and Sleep Number Corporation (paid to Mayo). He is a consultant for Bayer; Jazz; and Respicardia, Inc.

Kashemi D. Rorie, PhD (planning committee) has no disclosures to report.

Evan Luberger (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).